Sign Out
Subcutaneous Injection: Administration should be performed by an individual who has been trained in injection techniques. Patients should receive adequate calcium and vitamin D supplementation. No dose adjustment is required for patients with renal impairment.
Skeletal-related Events: 120 mg subcutaneous injection once every 4 weeks.
Giant Cell Tumor of the Bone: 120 mg subcutaneous every 4 weeks with additional 120 mg doses on days 8 and 15 of the first month of therapy.
Hypercalcemia of Malignancy: 120 mg subcutaneous every 4 weeks with additional 120 mg doses on days 8 and 15 of the first month of therapy.
